|
|||||
|
|
New Feature: See Wall Street analyst ratings directly on Finviz charts for deeper context into price action.
| Group | Order By |
![]() |
![]() |
| Overview | Valuation | Performance | Custom | Bar Chart | Spectrum | Charts | Maps |

| No. | Name | Market Cap | P/E | Fwd P/E | PEG | P/S | P/B | P/C | P/FCF | EPS past 5Y | EPS next 5Y | Sales past 5Y | Change | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Biotechnology | 1130.63B | 60.34 | 36.82 | 3.28 | 10.70 | 4.91 | 6.39 | 52.01 | -12.97% | 18.39% | 43.66% | -0.25% | 610.68M |
| 2 | Diagnostics & Research | 724.89B | 36.45 | 22.62 | 2.90 | 4.30 | 4.02 | 21.59 | 29.42 | 5.68% | 12.58% | 8.16% | -1.03% | 66.29M |
| 3 | Drug Manufacturers - General | 3955.51B | 26.12 | 15.79 | 2.12 | 5.35 | 7.25 | 28.82 | 24.29 | 20.38% | 12.31% | 10.21% | -0.98% | 131.57M |
| 4 | Drug Manufacturers - Specialty & Generic | 362.12B | 32.76 | 16.19 | 2.18 | 2.61 | 2.58 | 11.87 | 17.99 | 9.34% | 15.02% | 8.31% | -0.43% | 123.74M |
| 5 | Health Information Services | 86.63B | 57.14 | 25.91 | 2.85 | 2.48 | 3.33 | 6.24 | 21.63 | 14.55% | 20.05% | 22.33% | -0.79% | 52.73M |
| 6 | Healthcare Plans | 573.61B | 21.43 | 11.82 | 1.70 | 0.35 | 1.91 | 52.14 | 14.21 | -6.57% | 12.61% | 7.85% | -0.65% | 37.46M |
| 7 | Medical Care Facilities | 256.73B | 18.70 | 15.29 | 1.60 | 1.08 | 4.99 | 20.37 | 13.55 | 16.57% | 11.69% | 8.24% | 0.62% | 41.80M |
| 8 | Medical Devices | 912.25B | 34.77 | 19.49 | 2.91 | 3.77 | 3.69 | 17.99 | 29.19 | 7.19% | 11.94% | 9.83% | 0.19% | 143.12M |
| 9 | Medical Distribution | 250.22B | 31.63 | 19.72 | 2.30 | 0.25 | 44.71 | 30.63 | 12.81 | 35.94% | 13.73% | 9.30% | 0.94% | 7.08M |
| 10 | Medical Instruments & Supplies | 538.50B | 43.39 | 27.04 | 4.04 | 3.71 | 3.49 | 20.67 | 37.25 | 15.61% | 10.75% | 11.83% | 0.90% | 60.05M |
| 11 | Pharmaceutical Retailers | 310.88M | - | 14.15 | - | 0.43 | 1.65 | 3.90 | 28.87 | 1.42% | - | 32.19% | 2.22% | 606.02K |
| export |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite